GlassScriptPhysician profile
Sharon Henrikson
NPI 1679186407
$4,363.28
in general payments reported to CMS, 2019-2025
29 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.33 · 2023: $207 · 2024: $1,842 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,322.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.09 | 2023-2025 | |
| Novo Nordisk INC | $604.58 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $581.99 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $513.34 | 2023-2025 | |
| Lilly USA, LLC | $394.91 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $282.94 | 2023-2025 | Arexvy, Shingrix, Boostrix |
| Takeda Pharmaceuticals U.S.A., INC. | $144.60 | 2024-2025 | Trintellix |
| Lundbeck LLC | $127.66 | 2024-2025 | Vyepti |
| Phathom Pharmaceuticals, INC. | $111.50 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $106.91 | 2024-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $99.30 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $92.57 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.17 | 2024-2025 | Jardiance, Synjardy |
| Amgen INC. | $79.38 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $65.35 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $61.25 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $56.14 | 2024-2025 | |
| Radius Health, INC. | $52.64 | 2024-2025 | |
| Genentech USA, INC. | $40.33 | 2021 | |
| Astellas Pharma US INC | $37.86 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $30.94 | 2024-2025 | Auvelity |
| Ardelyx, INC. | $24.39 | 2024 | Ibsrela |
| Eisai INC. | $23.80 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.60 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $22.24 | 2025 | Watchman Access System |
| Baxter Healthcare | $18.14 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $18.00 | 2025 | Capvaxive, Enflonsia, Gardasil 9 |
| Currax Pharmaceuticals LLC | $14.14 | 2023 | Onzetra Xsail, Nexletol, Contrave |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Henrikson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.